Okay so as it sits now.
IME MC is $23m with $4.8m cash.
EV of $18m.
Total contracted value is at $21m.
Historically they earnt $4.5m last fy. $3.8m of that was recurring.
Since then we have had numerous large SaaS and PaaS contracts signed.
They have totalled $11m. Plus from the quarterly expenditure I expect there to be another significant PaaS deal signed this month.
I expect annualised revenues to now climb to $6m to $7m at this stage.
That really is massive for a $23m MC stock in the medical industry that is seeing exponential growth.
If we see finance sorted for the PaaS which will then take away the expenditure from our cash reserves and more expansion into multiple countries and verticals there will be no stopping this imo.
From the last contract announcement it seems they are close to finalising a finance arrangement for the PaaS expenditure and some news on pathology and cardiology verticals is due also. Expansion is also on track.
Feel free to add if I have missed anything.
Updated Figures
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
